The present disclosure relates to novel compounds, pharmaceutical compositions, and methods for treating or preventing microbial infection caused by parasites or bacteria, such as Plasmodium falciparum or related Plasmodium parasite species and Mycobacterium tuberculosis or related Mycobacterium bacteria species. The compounds are α,β-unsaturated analogs of fosmidomycin and can inhibit deoxyxylulose phosphate reductoisomerase (Dxr) in many microbes, such as P. falciparum.
本公开涉及新型化合物、药物组合物和用于治疗或预防由寄生虫或细菌引起的微
生物感染的方法,例如疟原虫或相关疟原虫物种以及结核分枝杆菌或相关分枝杆菌细菌物种。这些化合物是福斯
米多霉素的α,β-不饱和类似物,可以抑制多种微
生物中的脱氧
木糖醇磷酸还原异构酶(Dxr),例如疟原虫。